Does Semaglutide Cause Liver Damage — or Could It Help?

What official guidance and trials actually found

Concern about semaglutide and liver damage is understandable. GLP-1 medicines are relatively new at scale, and when something changes how your body processes food and fat, it is natural to wonder what that means for an organ that sits at the centre of metabolism. The good news is that the evidence points firmly in one direction.

The MHRA's approval of Wegovy for MASH, announced on 3 July 2026, followed trial data showing semaglutide reduced liver inflammation and reversed fibrosis (scarring) in a meaningful proportion of participants with moderate-to-advanced liver disease. This is the regulator responsible for licensing medicines in the UK concluding, after scrutinising safety data, that semaglutide is not only harmless to the liver but therapeutically useful for a condition that previously had very limited treatment options.

The STEP 1 trial, published in the New England Journal of Medicine, also recorded improvements in liver-fat markers alongside weight loss in the semaglutide group. Liver toxicity was not a reported finding. That trial enrolled over 1,900 adults and ran for 68 weeks, providing a reasonable signal that the liver tolerates semaglutide well in the weight-management setting.

The NHS medicines page for semaglutide lists the medicine's known side effects in detail; liver damage does not appear among them.

When existing liver disease changes the picture

None of the above means liver health is irrelevant to your consultation. The Wegovy SmPC advises caution in people with severe hepatic impairment, that is, serious pre-existing liver dysfunction, not ordinary raised liver enzymes or fatty liver. In practice, prescribers assess liver health as part of the full medical history before approving treatment.

Mild or moderate liver conditions, including non-alcoholic fatty liver disease (NAFLD, which overlaps with MASH), are not contraindications and may actually be among the reasons a prescriber considers semaglutide appropriate. If you want a closer look at how semaglutide interacts with the liver and what the research says about risk, that is worth reading before your consultation. If you have been told you have any form of liver disease, the right step is to be transparent on your consultation form so that a prescriber can weigh that against your full picture.

There is also an indirect point worth understanding: the GI effects of semaglutide (nausea, reduced appetite) can, if severe, lead to dehydration and reduced calorie intake. Very rarely, rapid or extreme dietary restriction can affect liver enzymes transiently. This is not a direct drug effect, but it is one reason prescribers monitor patients and why questions about semaglutide and liver issues sometimes arise in practice.

Pancreatitis: a separate concern that is worth knowing about

The question about liver damage sometimes arises alongside concern about pancreatitis, and it is worth separating the two. The pancreas and liver sit close together, and abdominal pain can point to either.

In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but serious known risk with GLP-1 receptor agonists. The key symptoms are severe, persistent pain in the upper abdomen that may spread to the back, sometimes accompanied by vomiting. This is different from the usual nausea or stomach discomfort that settles within the first few weeks of treatment. If you experience that kind of pain, stop the injection and get medical help promptly, do not wait for your next scheduled review. You can also report suspected side effects through the MHRA Yellow Card scheme.

Pancreatitis is not liver damage, but it can affect liver enzyme readings and cause diagnostic confusion. Being familiar with both helps you recognise when to act. People sometimes also ask whether Wegovy specifically can damage the liver, and that page sets out the evidence clearly if you want to work through that question separately. Explore the broader picture of whether Wegovy can damage your liver if you want a fuller look at the specific mechanisms involved.

Who to talk to, and what comes next

If you have an existing liver condition, or you have been flagged for abnormal liver function tests, your GP or hepatologist is the right first port of call. They can advise on whether a GLP-1 medicine fits your current treatment plan. For most people without significant liver disease, the evidence is reassuring: semaglutide has not been found to damage the liver and now carries a licence specifically for liver benefit.

If you are considering semaglutide for weight management and want to explore whether it is suitable for you, our prescribers at nume review every consultation personally on the day it is submitted. They read your health history (including anything you flag about your liver) before any prescription is issued. There is no algorithm making that call. A separate question that occasionally comes up at this stage is whether Wegovy can affect a pregnancy test result, which is worth knowing about if that is relevant to you. You can look at the full range of options on our weight-loss treatments page, or if you have further questions about the Wegovy pathway, our FAQs cover the most common ones.